In co\continuation of my update on Bortezomib...
The PANORAMA 2 trial included 53 patients with relapsed multiple
myeloma who had undergone multiple rounds of prior treatment and, in
more than half, also stem cell transplant. The researchers reported on 44 patients receiving the panobinostat-bortezomib-dexamethasone combination.
A phase 2 clinical trial has shown that pairing bortezomib with an
experimental drug, panobinostat: Panobinostat is a histone deacetylase (HDAC) inhibitor, a type of drug that blocks key processes involved in gene expression
and protein degradation. Panobinostat clogs up a protein disposal
mechanism in myeloma cells so that harmful byproducts accumulate and
eventually cause programmed cell death.(see below structure), may be a promising new treatment for
such patients, Dana-Farber Cancer Institute researchers say.
Results
showed that in the first phase of the treatment, 9 of the patients had
at least a partial response of their disease, and 2 of the 9 saw their
myeloma almost disappear, a so-called near complete response. Another 7
patients experienced minimal response, which is also associated with
clinical benefit.
More : http://ash.confex.com/ash/2011/webprogram/Paper41145.html
